Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has earned an average recommendation of “Moderate Buy” from the sixteen analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $215.3846.

Several equities analysts have recently issued reports on JAZZ shares. Barclays reiterated an “overweight” rating and set a $224.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, March 9th. Morgan Stanley boosted their target price on Jazz Pharmaceuticals from $225.00 to $226.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Piper Sandler raised their price target on Jazz Pharmaceuticals from $219.00 to $232.00 and gave the company an “overweight” rating in a report on Thursday, March 19th. TD Cowen reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Thursday, January 29th. Finally, Bank of America raised their price objective on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $182.69 on Friday. Jazz Pharmaceuticals has a 12 month low of $95.49 and a 12 month high of $198.00. The firm has a market capitalization of $11.25 billion, a P/E ratio of -30.60, a P/E/G ratio of 0.33 and a beta of 0.22. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.00. The business has a fifty day simple moving average of $175.63 and a two-hundred day simple moving average of $160.05.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The firm had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the prior year, the firm earned $6.51 EPS. The company’s revenue was up 8.1% compared to the same quarter last year. On average, equities analysts forecast that Jazz Pharmaceuticals will post 16.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Mary Elizabeth Henderson sold 5,343 shares of the company’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $194.49, for a total transaction of $1,039,160.07. Following the transaction, the senior vice president directly owned 28,728 shares of the company’s stock, valued at $5,587,308.72. This represents a 15.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Neena M. Patil sold 55,600 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $191.56, for a total value of $10,650,736.00. Following the completion of the sale, the executive vice president owned 56,862 shares of the company’s stock, valued at $10,892,484.72. The trade was a 49.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 68,015 shares of company stock valued at $13,037,486. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in JAZZ. Cardinal Capital Management boosted its holdings in Jazz Pharmaceuticals by 0.5% in the fourth quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock worth $2,471,000 after acquiring an additional 66 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 9.0% during the third quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 81 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Jazz Pharmaceuticals by 12.6% during the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock valued at $123,000 after acquiring an additional 81 shares in the last quarter. Tectonic Advisors LLC raised its position in shares of Jazz Pharmaceuticals by 1.5% in the 3rd quarter. Tectonic Advisors LLC now owns 5,626 shares of the specialty pharmaceutical company’s stock valued at $742,000 after purchasing an additional 82 shares during the last quarter. Finally, Pinnacle Associates Ltd. raised its position in shares of Jazz Pharmaceuticals by 0.7% in the 4th quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock valued at $1,905,000 after purchasing an additional 83 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.